Xtandi Shows Superior Survival Outcomes to Abiraterone in Treatment of Metastatic Castration-Resistant Prostate Cancer
Cohort study shows Xtandi (enzalutamide) achieved statistically significant improvements in overall survival vs. abiraterone acetate in the treatment of metastatic castration-resistant prostate cancer.
The Future of Clinical Technology
In the fifth and final part of this video interview, Melissa Easy, VP commercial, digital products & solutions, IQVIA shares what excites her most about the future of clinical technology.
Monjuvi Succeeds in Phase III Trial of Patients with Relapsed or Refractory Follicular Lymphoma
Incyte’s Monjuvi (tafasitamab) met its primary endpoint of progression free survival in the study.
Pfizer and BioNTech’s mRNA-Based Combination Vaccine Demonstrates Strong Immune Responses to Influenza A
Results from the joint Phase III clinical trial of the vaccine also demonstrated results comparable to the companies’ licensed COVID-19 vaccine.
How Regulators are Viewing the Current Landscape of Clinical Technology
In part 4 of this video interview, Melissa Easy, VP commercial, digital products & solutions, IQVIA highlights how the regulators are addressing new technology with updated guidances.
FDA Grants Breakthrough Therapy Designation, Priority Review to AstraZeneca’s Imfinzi for the Treatment of Limited-Stage Small Cell Lung Cancer
Priority review of Imfinzi was based on promising results from the ADRIATIC Phase III trial in patients with limited-stage small cell lung cancer whose disease has not progressed following platinum-based concurrent chemoradiotherapy.
Choosing the Best Clinical Technology for Your Study
In part 3 of this video interview, Melissa Easy, VP commercial, digital products & solutions, IQVIA touches on how the right technology for your study should alleviate site burden and improve data quality.
Integrating Clinical Technology
In part 2 of this video interview, Melissa Easy, VP commercial, digital products & solutions, IQVIA discusses how advancements in technology are creating challenges with integration and how they can be addressed.
'Fit-for-Purpose' Considerations for Remote Trials
Q&A with Joachim Lövin explores the challenges and lessons learned in boosting the flexibility of conducting decentralized clinical trials post-COVID.
Reqorsa Demonstrates Promising Results in Treating Patients with Small Cell Lung Cancer and Non-Small Cell Lung Cancer
Results demonstrated prolonged progression free survival of two patients in Acclaim-1 study and partial remission from maintenance therapy in Acclaim-3 study.
Rethinking Training: The Benefits of Embracing ‘Desirable Difficulties’
Four strategies for implementing this approach in clinical trial staff and site training.
Abrysvo Demonstrates Safety and Efficacy as an RSV Vaccine in Immunocompromised Adults
Results from the Phase III MONeT clinical trial found that Abrysvo was well tolerated in adults over the age of 18 years old.
Engaging Emerging Clinical Investigators Yields Unique Benefits for All
New investigators practicing in community-based settings bring enthusiasm and a fresh approach to clinical research, while also boosting collaboration and merging personal connection and patient-centric insights.
Excitement Around the Current State of Clinical Technology
In part 1 of this video interview, Melissa Easy, VP commercial, digital products & solutions, IQVIA highlights how patients, sites, and sponsors can benefit from recent advancements such as AI and LLMs.
Effective eConsent Strategies for Every Study: Utilizing the eConsent Fit-for-Purpose Study Framework
Designing eConsent for each study from a stakeholders’ value, not technology perspective.
Reproxalap Significantly Reduces Ocular Discomfort in a Phase III Clincal Trial for the Treatment of Dry Eye Disease
Results represent the first positive Phase III clinical trial in a dry eye chamber with a symptom as the primary endpoint.
Potential Advancements in Patient Centricity
In the fourth and final part of this video interview, Vincent Keunen, founder & CEO of Andaman7 looks forward and highlights some potential advancements with the use of AI.
Sarclisa Combination Produces Significantly Improved Progression-Free Survival in Newly Diagnosed Multiple Myeloma
Induction therapy comprised of Sarclisa (isatuximab-irfc; Sanofi) plus lenalidomide, bortezomib, and dexamethasone significantly improved progression-free survival from first randomization in transplant-eligible patients with newly diagnosed multiple myeloma.
Delivering Operational Excellence in a Complex Environment of CAR-Directed Cell Therapies
Overcoming saturation in the cell therapy landscape.
Identifying the Most Useful Features in Solutions from a Patient POV
In part 3 of this video interview, Vincent Keunen, founder & CEO of Andaman7 shares his own experience as a patient when it comes to using digital applications.
Merck Discontinues Phase III Trial of Keytruda Combination for SCLC
Patients in the Keytruda (pembrolizumab)-vibostolimab combo plus chemotherapy arm experienced a higher rate of adverse events compared to those in the control arm.
Nipocalimab Shows Significant Promise Treating Early-Onset Severe Hemolytic Disease of the Fetus and Newborn
Results show nipocalimab could address the high unmet need of patients with severe hemolytic disease of the fetus and newborn, which is a life-threatening and rare condition with no other therapies currently in clinical development.
Building Patient-centric Technology
In part 2 of this video interview, Vincent Keunen, founder & CEO of Andaman7 highlights how technology vendors should be keeping the patient in mind when building solutions.
Postsurgical Pain Candidate Vocacapsaicin Demonstrates Efficacy in Reducing Opioid Use
In a presentation at the 2024 International Association for the Study of Pain World Congress, Concentric Analgesics shared positive Phase II data for its lead candidate.
Addition of Olanzapine Improves Complete Response, Nausea and Vomiting Prevention in Chemotherapy-Naive Patients
Study shows efficacy of olanzapine in improving complete response rates and chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy regimens comprised of oxaliplatin, carboplatin, or irinotecan.
Current Challenges in Patient Centricity
In part 1 of this video interview, Vincent Keunen, founder & CEO of Andaman7 discusses how service providers and sponsors can make the lives of patients contributing to research easier.
Kerendia Achieves Reduction in Risk of Cardiovascular Death and Heart Failure
Phase III study of Bayer’s non-steroidal, selective mineralocorticoid receptor antagonist met its primary endpoint.
Trial Results Show Efficacy of Extended Dosing Tremfya in Clearance of Psoriasis
Tremfya dosing at an interval of every 16 weeks was noninferior to the standard every eight weeks dosing interval for maintenance of psoriasis disease control.
Delivering Better Outcomes for Patients with LLMs
In the fifth and final part of this video interview, Rama Kondru, PhD, CEO of Veridix AI looks forward to what the LLM landscape in clinical trials could look like in five years.
Eli Lilly’s Tirzepatide Shows Reduction in Risk of Heart Failure Outcomes
Phase III study of tirzepatide in adults with heart failure with preserved ejection fraction and obesity met all primary endpoints.
